Kolchinsky Peter — SEC insider filings

SEC reporting owner CIK 1384859. 294 insider filings on record with FilingPulse; latest filed 2026-11-18.

Transaction summary — filings shown

Covers the 50 most recent of 294 filings on record, filed 2026-05-14 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Parabilis Medicines, Inc. (PBLS)Director, 10% owner38 legs · 21,433,343 sh · $430,694,551—7
Septerna, Inc. (SEPN)Director, 10% owner2—2 legs · 1,493,000 sh · $63,452,5001
Bambusa Therapeutics, Inc. (BBTX)Director, 10% owner24 legs · 2,953,820 sh · $46,639,957—6
PepGen Inc. (PEPG)Director, 10% owner21 leg · 8,625,000 sh · $43,125,000—1
Sionna Therapeutics, Inc. (SION)Director, 10% owner2—2 legs · 3,448,811 sh · $21,835,0181
Artiva Biotherapeutics, Inc. (ARTV)Director, 10% owner1119 legs · 2,132,127 sh · $17,678,460—2
LENZ Therapeutics, Inc. (LENZ)10% owner2—3 legs · 2,718,684 sh · $9,134,7781
Hemab Therapeutics Holdings, Inc. (COAG)10% owner35 legs · 78,854 sh · $1,968,631——
Werewolf Therapeutics, Inc. (HOWL)10% owner3—14 legs · 1,543,973 sh · $573,245—
SpyGlass Pharma, Inc. (SGP)Director, 10% owner11 leg · 1,000 sh · $32,430——

+12 more issuers among the filings shown — every filing appears in the table below.

Insider filings — Kolchinsky Peter

FiledFormIssuerReported transactionsSource
2026-11-184SpyGlass Pharma, Inc. (SGP)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Purchase (P): 1,000 @ $32.43EDGAR
2026-11-174PepGen Inc. (PEPG)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M.
Purchase (P): 8,625,000 @ $5EDGAR
2026-11-034Bambusa Therapeutics, Inc. (BBTX)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Purchase (P): 189,909 @ $14.23 · Purchase (P): 263,911 @ $14.92 · Conversion (C): 3,144,858 · Conversion (C): 1,331,080 · Purchase (P): 2,335,109 @ $16 · Purchase (P): 164,891 @ $16 · +4 moreEDGAR
2026-11-024LENZ Therapeutics, Inc. (LENZ)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Sale (S): 2,159,516 @ $3.36 · Sale (S): 451,998 @ $3.36 · Sale (S): 107,170 @ $3.36EDGAR
2026-10-293Bambusa Therapeutics, Inc. (BBTX)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Holdings only — no transactions reportedEDGAR
2026-10-074Wave Life Sciences, Inc. (WVE)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Grant/award (A): 10,700 @ $0 · Grant/award (A): 64,000 (derivative) @ $0EDGAR
2026-10-054Vor Biopharma Inc. (VOR)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Option exercise (M): 500 @ $12.80 · Option exercise (M): 500 (derivative) @ $0EDGAR
2026-09-304Climb Bio, Inc. (CLYM)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Option exercise (M): 10,000 @ $3.46 · Option exercise (M): 10,000 @ $3 · Option exercise (M): 10,000 @ $7.89 · Option exercise (M): 40,000 @ $1.29 · Option exercise (M): 10,000 (derivative) @ $0 · Option exercise (M): 10,000 (derivative) @ $0 · +2 moreEDGAR
2026-09-214Sionna Therapeutics, Inc. (SION)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Sale (S): 3,415,011 @ $6.32 · Sale (S): 33,800 @ $7.46EDGAR
2026-09-174Tyra Biosciences, Inc. (TYRA)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Shah Rajeev M.
Purchase (P): 9,078,529 (derivative) @ $22.03EDGAR
2026-09-144Artiva Biotherapeutics, Inc. (ARTV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Grant/award (A): 16,250 (derivative) @ $0EDGAR
2026-09-084Artiva Biotherapeutics, Inc. (ARTV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Grant/award (A): 13,750 (derivative) @ $0EDGAR
2026-08-264Vor Biopharma Inc. (VOR)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Option exercise (M): 1,500 @ $3.74 · Option exercise (M): 1,500 (derivative) @ $0EDGAR
2026-08-144Septerna, Inc. (SEPN)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Sale (S): 746,500 @ $42.50 · Sale (S): 746,500 @ $42.50EDGAR
2026-07-314Inhibikase Therapeutics, Inc. (IKT)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Other (J): 18,030,000 · Other (J): 18,030,000 (derivative)EDGAR
2026-07-314Artiva Biotherapeutics, Inc. (ARTV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Purchase (P): 20,824 @ $9.99 · Purchase (P): 24,944 @ $9.93EDGAR
2026-07-284Artiva Biotherapeutics, Inc. (ARTV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Purchase (P): 41,319 @ $9.99EDGAR
2026-07-234/AArtiva Biotherapeutics, Inc. (ARTV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Purchase (P): 6,522 @ $8.94EDGAR
2026-07-234Artiva Biotherapeutics, Inc. (ARTV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Purchase (P): 120,582 @ $9.55 · Purchase (P): 84,124 @ $9.93 · Purchase (P): 59,880 @ $9.96EDGAR
2026-07-224Parabilis Medicines, Inc. (PBLS)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Purchase (P): 98,433 @ $27.13 · Purchase (P): 32,987 @ $27.72 · Purchase (P): 21,696 @ $27.96 · Purchase (P): 6,504 @ $29.17 · Purchase (P): 37,723 @ $30 · Purchase (P): 47,250 @ $29.77EDGAR
2026-07-224Freenome, Inc. (FRNM)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Grant/award (A): 6,561,711 · Grant/award (A): 970,950 · Grant/award (A): 553,703 · Grant/award (A): 908,103 · Grant/award (A): 367,427 · Grant/award (A): 4,918,411 @ $10 · +1 moreEDGAR
2026-07-214Vor Biopharma Inc. (VOR)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Option exercise/expiry (X): 2,100,000 @ $0.00 · Sale (S): 213 @ $19.75 · Option exercise/expiry (X): 2,100,000 (derivative) @ $5EDGAR
2026-07-204Artiva Biotherapeutics, Inc. (ARTV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Purchase (P): 152,472 @ $8.93 · Purchase (P): 7,882 @ $8.95EDGAR
2026-07-144Artiva Biotherapeutics, Inc. (ARTV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Purchase (P): 15,102 @ $8.97 · Purchase (P): 6,552 @ $8.94EDGAR
2026-07-014Climb Bio, Inc. (CLYM)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Grant/award (A): 70,284 (derivative) @ $0EDGAR
2026-06-304Septerna, Inc. (SEPN)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Grant/award (A): 15,000 (derivative) @ $0EDGAR
2026-06-294Artiva Biotherapeutics, Inc. (ARTV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Purchase (P): 31,000 @ $8.88 · Purchase (P): 1,876 @ $8.98EDGAR
2026-06-264ARS Pharmaceuticals, Inc. (SPRY)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M.
Grant/award (A): 30,000 (derivative) @ $0EDGAR
2026-06-224PepGen Inc. (PEPG)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M.
Grant/award (A): 34,000 (derivative) @ $0EDGAR
2026-06-224Acrivon Therapeutics, Inc. (ACRV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M.
Grant/award (A): 20,275 (derivative) @ $0EDGAR
2026-06-224Werewolf Therapeutics, Inc. (HOWL)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Sale (S): 389,216 @ $0.35 · Sale (S): 27,695 @ $0.35EDGAR
2026-06-184Sionna Therapeutics, Inc. (SION)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Grant/award (A): 17,340 (derivative) @ $0EDGAR
2026-06-174Hemab Therapeutics Holdings, Inc. (COAG)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Purchase (P): 6,146 @ $24.89 · Purchase (P): 61,523 @ $24.98EDGAR
2026-06-164Werewolf Therapeutics, Inc. (HOWL)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Sale (S): 159,119 @ $0.40 · Sale (S): 11,322 @ $0.40 · Sale (S): 120,216 @ $0.39 · Sale (S): 8,554 @ $0.39 · Sale (S): 139,686 @ $0.37 · Sale (S): 9,939 @ $0.37EDGAR
2026-06-164Artiva Biotherapeutics, Inc. (ARTV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Purchase (P): 391,019 @ $8.57 · Purchase (P): 15,414 @ $8.99 · Purchase (P): 124,893 @ $8.89EDGAR
2026-06-154Parabilis Medicines, Inc. (PBLS)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Conversion (C): 6,556,740 · Conversion (C): 1,187,881 · Purchase (P): 19,728,353 @ $20 · Purchase (P): 1,460,397 @ $20 · Conversion (C): 642,250 (derivative) · Conversion (C): 160,562 (derivative) · +2 moreEDGAR
2026-06-154LENZ Therapeutics, Inc. (LENZ)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M.
Grant/award (A): 22,100 (derivative) @ $0EDGAR
2026-06-124Janux Therapeutics, Inc. (JANX)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M.
Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0EDGAR
2026-06-124Vor Biopharma Inc. (VOR)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Grant/award (A): 57,162 (derivative) @ $0EDGAR
2026-06-114Nkarta, Inc. (NKTX)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Shah Rajeev M.
Grant/award (A): 37,000 (derivative) @ $0EDGAR
2026-06-114Parabilis Medicines, Inc. (PBLS)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Grant/award (A): 20,215 (derivative) @ $0EDGAR
2026-06-114Artiva Biotherapeutics, Inc. (ARTV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Purchase (P): 479,039 @ $6.91 · Purchase (P): 103 @ $7 · Purchase (P): 548,580 @ $7.91EDGAR
2026-06-114Werewolf Therapeutics, Inc. (HOWL)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Sale (S): 345,235 @ $0.37 · Sale (S): 24,565 @ $0.37 · Sale (S): 42,872 @ $0.37 · Sale (S): 3,051 @ $0.37 · Sale (S): 245,066 @ $0.38 · Sale (S): 17,437 @ $0.38EDGAR
2026-06-104Bicara Therapeutics Inc. (BCAX)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Grant/award (A): 19,475 (derivative) @ $0EDGAR
2026-06-084Climb Bio, Inc. (CLYM)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M.
Grant/award (A): 40,000 (derivative) @ $0EDGAR
2026-06-054Acumen Pharmaceuticals, Inc. (ABOS)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M.
Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0EDGAR
2026-06-014Tyra Biosciences, Inc. (TYRA)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Shah Rajeev M.
Grant/award (A): 13,160 (derivative) @ $0EDGAR
2026-05-214Hemab Therapeutics Holdings, Inc. (COAG)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Purchase (P): 3,802 @ $24.97 · Purchase (P): 996 @ $24.94EDGAR
2026-05-204Acrivon Therapeutics, Inc. (ACRV)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M.
Grant/award (A): 9,366 @ $0EDGAR
2026-05-144Hemab Therapeutics Holdings, Inc. (COAG)
jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M.
Purchase (P): 6,387 @ $24.90EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-08-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1384859 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs